Nachrichten zur PhotoCure ASA Aktie

Photocure ASA – Notice of the Annual General Meeting 23 May 2024

Oslo, Norway, 30 April 2024: Photocure ASA (OSE: PHO), calls for the annual general meeting of Photocure ASA to be…

Photocure ASA: Annual Report 2023

Oslo, Norway, 30 April 2024: Photocure ASA today announces the publication of the Annual Report and integrated ESG report for…

Photocure ASA reports Q4 results

…

Photocure ASA: Change of Board Composition

Oslo, Norway, 28 September 2023: Photocure, The Bladder Cancer Company, announces changes to the composition of its Board of Directors.…

Photocure Partner Asieris announces that the First Non-Vaccine Investigational Product for Cervical HSIL has Achieved Its Primary Endpoint

Press Release – Oslo, Norway, September 20, 2023: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner…

Photocure Partner Asieris confirms Hexvix Phase III clinical trial in China meets endpoint

Press Release – Oslo, Norway, August 11, 2023: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner…

Photocure ASA reports Q2 results

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Photocure ASA: Results for the second quarter and first half of 2023

OSLO, Norway, Aug. 9, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 115.9 million in…

Photocure ASA: Results for the second quarter and first half of 2023

Oslo, Norway, 9 August 2023 - Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 115.9 million in the second…

Photocure ASA: Invitation to presentation of second quarter and first half year 2023 financial results

Oslo, Norway, 3 August 2023: Photocure ASA (Photocure, PHO: OSE) will announce the second quarter and first half year 2023…

Photocure Partner Asieris announces completion of enrollment for Hexvix Phase III clinical trial in China

Press Release – Oslo, Norway, July 6, 2023: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner…

Photocure ASA – Share option grant

Oslo, Norway, 24 May 2023 - Photocure ASA (the "Company") (OSE: PHO) has granted share options to employees. A total of…

Photocure ASA: Results for the first quarter of 2023

OSLO, Norway, May 10, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 105.9 million in…

Photocure ASA: Results for the first quarter of 2023

Oslo, Norway, 10 May 2023 - Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 105.9 million in the first…

Photocure ASA - Correction: Annual general meeting held

OSLO, Norway, May 4, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), held its annual general meeting on 3 May 2023…

Photocure ASA – Correction: Annual general meeting held

Oslo, Norway, 3 May 2023: Photocure ASA (OSE: PHO), held its annual general meeting on 3 May 2023 at 17:00…

Photocure ASA - Annual general meeting held

OSLO, Norway, May 3, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), held its annual general meeting on 3 May 2023…

Photocure ASA – Annual general meeting held

Oslo, Norway, 3 May 2023: Photocure ASA (OSE: PHO), held its annual general meeting on 3 May 2023 at 17:00…

Photocure ASA: Invitation to presentation of first quarter 2023 financial results

OSLO, Norway, May 3, 2023 /PRNewswire/ -- Photocure ASA (Photocure) (PHO: OSE) will announce the first quarter 2023 financial results…

Photocure ASA: Invitation to presentation of first quarter 2023 financial results

Oslo, Norway, 3 May 2023: Photocure ASA (Photocure, PHO: OSE) will announce the first quarter 2023 financial results on Wednesday…

Photocure: Nordic registry clinical data and multiple scientific programs at AUA 2023 Congress reinforce the benefits of Blue Light Cystoscopy

Press Release – Oslo, Norway, May 2, 2023: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that results from…

Photocure ASA: Annual Report 2022

OSLO, Norway, April 12, 2023 /PRNewswire/ -- Photocure ASA today announces the publication of the Annual Report and integrated ESG…

Photocure ASA - Notice of the Annual General Meeting 3 May 2023

OSLO, Norway, April 12, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), calls for the annual general meeting of Photocure ASA…

Photocure ASA – Notice of the Annual General Meeting 3 May 2023

Oslo, Norway, 12 April 2023: Photocure ASA (OSE: PHO), calls for the annual general meeting of Photocure ASA to be…

Photocure ASA: Annual Report 2022

Oslo, Norway, 12 April 2023: Photocure ASA today announces the publication of the Annual Report and integrated ESG report for…

Photocure ASA – Share option grant

Oslo, Norway, 30 March 2023 - Photocure ASA (the "Company") (OSE: PHO) has granted share options to employees. A total of…

Photocure: New data presented at EAU 2023 highlight the effects of blue light cystoscopy in bladder cancer

Oslo, Norway, March 14, 2023: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces its participation in the congress, and…

Photocure ASA: Results for the fourth quarter of 2022

OSLO, Norway, Feb. 23, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 94.9 million in…

Photocure ASA: Results for the fourth quarter of 2022

Oslo, Norway, 23 February 2023 Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 94.9 million in the fourth quarter…

Clinical data presented at ASCO GU demonstrates reduced risk of recurrence in non-muscle invasive bladder cancer with the use of BLC

OSLO, Norway, Feb. 20, 2023 /PRNewswire/ -- Photocure ASA, The Bladder Cancer Company, announces the presentation of clinical data from…

Clinical data presented at ASCO GU demonstrates reduced risk of recurrence in non-muscle invasive bladder cancer with the use of BLC

Press release – Oslo, Norway, February 20, 2023: Photocure ASA, The Bladder Cancer Company, announces the presentation of clinical data…

Photocure ASA: Invitation to presentation of 4th quarter and preliminary full year 2022 financial results

Oslo, Norway, 16 February 2023: Photocure ASA (Photocure, PHO: OSE) will announce the fourth quarter and preliminary full year 2022…

New study publication reinforces the clinical benefits of Blue Light Cystoscopy in the ASC setting; supports ongoing initiatives to further improve reimbursement

OSLO, Norway, Jan. 3, 2023 /PRNewswire/ -- Photocure ASA, The Bladder Cancer Company, announces the publication of the study Clinical…

New study publication reinforces the clinical benefits of Blue Light Cystoscopy in the ASC setting; supports ongoing initiatives to further improve reimbursement

Press release – Oslo, Norway, January 3, 2023: Photocure ASA, The Bladder Cancer Company, announces the publication of the study…

New Evidence: Positive Impact of Blue Light Cystoscopy on Recurrence in Bladder Cancer Presented at the Annual SUO Meeting

OSLO, Norway, Dec. 5, 2022 /PRNewswire/ -- Photocure ASA, The Bladder Cancer Company, announces that new evidence was presented at…

New Evidence: Positive Impact of Blue Light Cystoscopy on Recurrence in Bladder Cancer Presented at the Annual SUO Meeting

Press release – Oslo, Norway, December 5th, 2022: Photocure ASA, The Bladder Cancer Company, announces that new evidence was presented…

Photocure: CMS improves Medicare reimbursement for Blue Light Cystoscopy with Cysview and expands access in the surveillance setting

OSLO, Norway, Nov. 7, 2022 /PRNewswire/ -- Photocure ASA., (OSE: PHO), announces that The United States Centers for Medicare &…

Photocure: CMS improves Medicare reimbursement for Blue Light Cystoscopy with Cysview and expands access in the surveillance setting

Oslo, Norway, November 7, 2022: Photocure ASA., (OSE: PHO), announces that The United States Centers for Medicare & Medicaid Services…

Photocure Partner Asieris announces 1[st] Patient enrolled in Hexvix Phase III trial in China

Press Release – Oslo, Norway, November 4, 2022: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner…

Photocure ASA: Results for the third quarter of 2022

OSLO, Norway, Nov. 2, 2022 /PRNewswire/ -- Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 96.9 million in the…

Photocure ASA: Results for the third quarter of 2022

Oslo, Norway, 2 November 2022: Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 96.9 million in the third quarter…

Photocure ASA: Invitation to presentation of third quarter 2022 financial results

Oslo, Norway, 25 October 2022: Photocure ASA (Photocure, PHO: OSE) will announce the third quarter 2022 financial results on Wednesday…

Data presented at the International Bladder Cancer Network (IBCN) meeting demonstrate a reduction in the risk of recurrence with the use of BLC

OSLO, Norway, Oct. 4, 2022 /PRNewswire/ -- Photocure ASA, The Bladder Cancer Company, announces the presentation of clinical data and…

Data presented at the International Bladder Cancer Network (IBCN) meeting demonstrate a reduction in the risk of recurrence with the use of BLC

Press release – Oslo, Norway, October 4, 2022: Photocure ASA, The Bladder Cancer Company, announces the presentation of clinical data…